OGEN 2.5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OGEN 2.5 (OGEN 2.5).
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
| Metabolism | Hepatic metabolism via CYP3A4 and other cytochrome P450 enzymes; undergoes enterohepatic recirculation. |
| Excretion | Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged. |
| Half-life | 10-24 hours; terminal half-life may be prolonged in hepatic impairment. |
| Protein binding | 50-60% bound to albumin; no specific binding protein. |
| Volume of Distribution | 12-86 L/kg; widely distributed due to lipophilicity. |
| Bioavailability | 30-50% after oral administration due to first-pass metabolism. |
| Onset of Action | 2-4 weeks for systemic estrogenic effects; variable depending on endpoint. |
| Duration of Action | 24-48 hours for endometrial effects; requires daily dosing for steady state. |
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
| Dosage form | TABLET |
| Renal impairment | Not studied; avoid in severe renal impairment (CrCl <30 mL/min) due to decreased clearance. |
| Liver impairment | Child-Pugh A: no adjustment; B/C: contraindicated due to impaired metabolism. |
| Pediatric use | Not indicated for pediatric use; safety and efficacy not established. |
| Geriatric use | Use lowest effective dose for shortest duration; consider increased risk of thromboembolic events and dementia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OGEN 2.5 (OGEN 2.5).
| Breastfeeding | Estropipate is excreted in human milk in low amounts (M/P ratio not established). Case reports suggest minimal transfer. However, estrogens may suppress lactation and affect milk composition. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period due to potential effects on milk production. Discuss with patient individual risk-benefit. |
| Teratogenic Risk | FDA Pregnancy Category X. Estrogens are contraindicated in pregnancy due to increased risk of fetal harm. First trimester: Associations with congenital anomalies (e.g., cardiovascular defects, limb reduction defects). Second and third trimesters: Potential for urogenital tract abnormalities, delayed development, and increased risk of vaginal adenosis and clear-cell carcinoma in female offspring. Use during pregnancy is not indicated. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women. Use unopposed estrogens only in women with a hysterectomy. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) studies reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women (50-79 years) receiving conjugated equine estrogens alone or with medroxyprogesterone acetate.
| Serious Effects |
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of thromboembolic disorders; active or recent arterial thromboembolic disease; known thrombophilic disorders; hepatic impairment or disease; known or suspected pregnancy; hypersensitivity to any ingredient.
| Precautions | Increased risk of endometrial cancer, cardiovascular disorders, stroke, thromboembolism, dementia, breast cancer (with combined therapy), gallbladder disease, hypercalcemia, visual abnormalities, and exacerbation of endometriosis. Use lowest effective dose for shortest duration. |
Loading safety data…
| Fetal Monitoring | If inadvertent exposure occurs during pregnancy, monitor fetal development with ultrasound (anatomy scan) and consider fetal echocardiogram due to potential cardiac effects. No routine monitoring indicated for therapeutic use as drug is contraindicated. In lactation, monitor infant for signs of estrogen effects (e.g., breast enlargement, vaginal bleeding). |
| Fertility Effects | Estrogen-containing products can inhibit ovulation via negative feedback on gonadotropin secretion, potentially reducing fertility. Upon discontinuation, fertility typically returns. No known permanent effects on fertility. Use as hormone therapy in postmenopausal women has no impact on fertility. |